{"transactions":[{"id":4640755,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-15T01:37:35.000Z","date":"2026-10-12","kind":"sale","planned":false,"acquired":false,"shares":1087,"price":28.05,"value":30490.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a \"sell-to-cover\" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold."}],"balance_after":694908,"source":{"system":"sec-edgar","filing":"0001725092-26-000019","document":"form4-10152026_011031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000172509226000019/form4-10152026_011031.xml","form_type":"4"}},{"id":4640754,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-15T01:37:35.000Z","date":"2026-10-12","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":27.5,"value":275000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a \"sell-to-cover\" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold."}],"balance_after":695995,"source":{"system":"sec-edgar","filing":"0001725092-26-000019","document":"form4-10152026_011031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000172509226000019/form4-10152026_011031.xml","form_type":"4"}},{"id":686475,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-15T00:46:04.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":false,"shares":109179,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The performance stock units (\"PSU\") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 12, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The performance stock units (\"PSU\") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 12, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The performance stock units (\"PSU\") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 12, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days."}],"balance_after":218358,"derivative":{"underlying":"Common Stock","underlying_shares":109179},"source":{"system":"sec-edgar","filing":"0001725092-26-000013","document":"form4-08152026_120800.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000013/form4-08152026_120800.xml","form_type":"4"}},{"id":686474,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-15T00:46:04.000Z","date":"2026-08-13","kind":"sale","planned":false,"acquired":false,"shares":10460,"price":29.48,"value":308360.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $28.90 to $29.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades."}],"balance_after":705995,"source":{"system":"sec-edgar","filing":"0001725092-26-000013","document":"form4-08152026_120800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000013/form4-08152026_120800.xml","form_type":"4"}},{"id":686473,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-15T00:46:04.000Z","date":"2026-08-13","kind":"sale","planned":false,"acquired":false,"shares":2375,"price":28.11,"value":66761.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $27.78 to $28.505, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades."}],"balance_after":716455,"source":{"system":"sec-edgar","filing":"0001725092-26-000013","document":"form4-08152026_120800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000013/form4-08152026_120800.xml","form_type":"4"}},{"id":686472,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-15T00:46:04.000Z","date":"2026-08-13","kind":"sale","planned":false,"acquired":false,"shares":5423,"price":27.19,"value":147451.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $26.70 to $27.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades."}],"balance_after":718830,"source":{"system":"sec-edgar","filing":"0001725092-26-000013","document":"form4-08152026_120800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000013/form4-08152026_120800.xml","form_type":"4"}},{"id":686471,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-15T00:46:04.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":5775,"price":27.75,"value":160256.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $27.50 to $28.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades."}],"balance_after":724253,"source":{"system":"sec-edgar","filing":"0001725092-26-000013","document":"form4-08152026_120800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000013/form4-08152026_120800.xml","form_type":"4"}},{"id":686470,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-15T00:46:04.000Z","date":"2026-08-12","kind":"sale","planned":false,"acquired":false,"shares":34225,"price":26.99,"value":923732.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a \"sell-to-cover\" transaction and do not represent discretionary transactions by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $26.50 to $27.495, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades."}],"balance_after":730028,"source":{"system":"sec-edgar","filing":"0001725092-26-000013","document":"form4-08152026_120800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000013/form4-08152026_120800.xml","form_type":"4"}},{"id":686469,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-15T00:46:04.000Z","date":"2026-08-12","kind":"exercise","planned":false,"acquired":true,"shares":109179,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":764253,"source":{"system":"sec-edgar","filing":"0001725092-26-000013","document":"form4-08152026_120800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000013/form4-08152026_120800.xml","form_type":"4"}},{"id":700495,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock Warrants (Right to Buy)","published_at":"2026-07-30T20:35:56.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":45453,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amendment is filed solely to correct the transaction code reported in Column 4 of Table II. The transactions reported herein were approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended, prior to the issuance of the applicable securities. All other information in the original filing remains unchanged."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On April 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023."}],"balance_after":45453,"derivative":{"exercise_price":11,"exercise_date":"2026-06-01","expiration_date":"2031-05-04","underlying":"Common Stock","underlying_shares":45453},"source":{"system":"sec-edgar","filing":"0001725092-26-000009","document":"form4a-07302026_080752.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000009/form4a-07302026_080752.xml","form_type":"4/A","original_submission_date":"2026-06-01"}},{"id":700494,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2026-07-30T20:35:56.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":90906,"price":11,"value":999966.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amendment is filed solely to correct the transaction code reported in Column 4 of Table II. The transactions reported herein were approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended, prior to the issuance of the applicable securities. All other information in the original filing remains unchanged."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On April 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The securities do not have an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023."}],"balance_after":90906,"derivative":{"exercise_price":0.001,"exercise_date":"2026-06-01","underlying":"Common Stock","underlying_shares":90906},"source":{"system":"sec-edgar","filing":"0001725092-26-000009","document":"form4a-07302026_080752.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000009/form4a-07302026_080752.xml","form_type":"4/A","original_submission_date":"2026-06-01"}},{"id":711015,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-10T23:32:15.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":327537,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents the grant of performance stock units (\"PSUs\"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents the grant of performance stock units (\"PSUs\"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents the grant of performance stock units (\"PSUs\"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration."}],"balance_after":327537,"derivative":{"underlying":"Common Stock","underlying_shares":327537},"source":{"system":"sec-edgar","filing":"0001725092-26-000006","document":"form4-07102026_110711.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000006/form4-07102026_110711.xml","form_type":"4"}},{"id":711014,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-10T23:32:15.000Z","date":"2026-07-09","kind":"grant","planned":false,"acquired":true,"shares":327537,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents that grant of restricted stock units (\"RSUs\").  The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date."}],"balance_after":655074,"source":{"system":"sec-edgar","filing":"0001725092-26-000006","document":"form4-07102026_110711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000006/form4-07102026_110711.xml","form_type":"4"}},{"id":750814,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock Warrants (Right to Buy)","published_at":"2026-06-03T21:30:17.000Z","date":"2026-06-01","kind":"purchase","planned":false,"acquired":true,"shares":45453,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023."}],"balance_after":45453,"derivative":{"exercise_price":11,"exercise_date":"2026-06-01","expiration_date":"2031-05-04","underlying":"Common Stock","underlying_shares":45453},"source":{"system":"sec-edgar","filing":"0001725092-26-000004","document":"form4-06032026_090611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000004/form4-06032026_090611.xml","form_type":"4"}},{"id":750813,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2026-06-03T21:30:17.000Z","date":"2026-06-01","kind":"purchase","planned":false,"acquired":true,"shares":90906,"price":11,"value":999966.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On April 30, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The securities do not have an expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023."}],"balance_after":90906,"derivative":{"exercise_price":0.001,"exercise_date":"2026-06-01","underlying":"Common Stock","underlying_shares":90906},"source":{"system":"sec-edgar","filing":"0001725092-26-000004","document":"form4-06032026_090611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000172509226000004/form4-06032026_090611.xml","form_type":"4"}},{"id":788223,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-07T20:00:05.000Z","date":"2026-05-03","kind":"grant","planned":false,"acquired":true,"shares":655074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in 48 equal monthly installments beginning on April 30, 2026."}],"balance_after":655074,"derivative":{"exercise_price":30.42,"expiration_date":"2036-05-02","underlying":"Common Stock","underlying_shares":655074},"source":{"system":"sec-edgar","filing":"0001193125-26-211806","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526211806/ownership.xml","form_type":"4"}},{"id":788222,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-05-07T20:00:05.000Z","date":"2026-05-03","kind":"grant","planned":false,"acquired":true,"shares":327537,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":327537,"source":{"system":"sec-edgar","filing":"0001193125-26-211806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526211806/ownership.xml","form_type":"4"}},{"id":1146906,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-05-15T21:19:11.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":1333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director."}],"balance_after":1333,"derivative":{"exercise_price":6.5,"exercise_date":"2026-05-14","expiration_date":"2035-05-14","underlying":"Common Stock","underlying_shares":1333},"source":{"system":"sec-edgar","filing":"0001593968-25-000609","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000159396825000609/primary_01.xml","form_type":"4"}},{"id":1488012,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-06-07T00:31:56.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":1333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director."}],"balance_after":1333,"derivative":{"exercise_price":11,"exercise_date":"2025-06-05","expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":1333},"source":{"system":"sec-edgar","filing":"0001593968-24-000833","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000159396824000833/primary_01.xml","form_type":"4"}},{"id":1548484,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-04-03T22:18:01.000Z","date":"2024-04-01","kind":"sale","planned":false,"acquired":false,"shares":9961,"price":6.6283,"value":66024.4963,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain Restricted Stock Units, and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $6.655 and no less than $6.600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1577374,"source":{"system":"sec-edgar","filing":"0001962918-24-000036","document":"wk-form4_1712182665.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000196291824000036/wk-form4_1712182665.xml","form_type":"4"}},{"id":1624530,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-23T00:04:47.000Z","date":"2024-02-20","kind":"sale","planned":false,"acquired":false,"shares":15701,"price":7.6048,"value":119402.9648,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain Restricted Stock Units, and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $7.75 and no less than $7.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1587335,"source":{"system":"sec-edgar","filing":"0001962918-24-000015","document":"wk-form4_1708646670.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000196291824000015/wk-form4_1708646670.xml","form_type":"4"}},{"id":1680535,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-11T23:42:40.000Z","date":"2024-01-09","kind":"grant","planned":false,"acquired":true,"shares":413498,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the option shall vest on July 9, 2025 if on that date the 30-day volume weighted average price of the Issuer's Common Stock for the immediately preceding 30 days meets or exceeds $22.00 per share, subject to the Reporting Person's continued service as of such vesting date, with such option being forfeited if such goal is not achieved."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All of the shares subject to the option shall vest on July 9, 2025 if on that date the 30-day volume weighted average price of the Issuer's Common Stock for the immediately preceding 30 days meets or exceeds $22.00 per share, subject to the Reporting Person's continued service as of such vesting date, with such option being forfeited if such goal is not achieved."}],"balance_after":413498,"derivative":{"exercise_price":7.68,"expiration_date":"2034-01-08","underlying":"Common Stock","underlying_shares":413498},"source":{"system":"sec-edgar","filing":"0001962918-24-000012","document":"wk-form4_1705016551.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000196291824000012/wk-form4_1705016551.xml","form_type":"4"}},{"id":1680534,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-11T23:42:40.000Z","date":"2024-01-09","kind":"grant","planned":false,"acquired":true,"shares":964829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4 of the shares subject to the option vest on January 9, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."}],"balance_after":964829,"derivative":{"exercise_price":7.68,"expiration_date":"2034-01-08","underlying":"Common Stock","underlying_shares":964829},"source":{"system":"sec-edgar","filing":"0001962918-24-000012","document":"wk-form4_1705016551.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000196291824000012/wk-form4_1705016551.xml","form_type":"4"}},{"id":1686856,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-04T23:09:03.000Z","date":"2024-01-02","kind":"sale","planned":false,"acquired":false,"shares":10691,"price":7.407,"value":79188.237,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain Restricted Stock Units, and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $7.62 and no less than $7.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,293 shares of Common Stock acquired pursuant to the Issuer's 2023 Employee Stock Purchase Plan (\"ESPP\"), for the purchase period of June 15, 2023 to December 14, 2023. This transaction is exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's Common Stock on December 14, 2023."}],"balance_after":1603036,"source":{"system":"sec-edgar","filing":"0001962918-24-000002","document":"wk-form4_1704409733.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000196291824000002/wk-form4_1704409733.xml","form_type":"4"}},{"id":1763253,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-10-06T21:55:39.000Z","date":"2023-10-04","kind":"other","planned":false,"acquired":true,"shares":132236,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"As part of its dissolution, Woodland Hills Partner LLC (the \"LLC\"), distributed its 1,161,747 shares of common stock to its limited partners. As part of that distribution, 132,236 shares were distributed to the Shao-Lee Lin 2020 Gift Trust Dtd 7/16/20. This distribution arises from the purchase of preferred stock by the Reporting Person as a limited partner in the LLC on the same pricing terms as the other participating investors in each round of financing. The remaining 1,029,511 shares were distributed to other LLC limited partners not under the ownership or control of, or otherwise affiliated with, the Reporting Person. As a result, those 1,029,511 shares are no longer beneficially owned by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Shao-Lee Lin 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse serves as trustee."}],"balance_after":487205,"source":{"system":"sec-edgar","filing":"0001962918-23-000036","document":"wk-form4_1696629327.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000196291823000036/wk-form4_1696629327.xml","form_type":"4"}},{"id":1763252,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-10-06T21:55:39.000Z","date":"2023-10-04","kind":"other","planned":false,"acquired":false,"shares":1161747,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"As part of its dissolution, Woodland Hills Partner LLC (the \"LLC\"), distributed its 1,161,747 shares of common stock to its limited partners. As part of that distribution, 132,236 shares were distributed to the Shao-Lee Lin 2020 Gift Trust Dtd 7/16/20. This distribution arises from the purchase of preferred stock by the Reporting Person as a limited partner in the LLC on the same pricing terms as the other participating investors in each round of financing. The remaining 1,029,511 shares were distributed to other LLC limited partners not under the ownership or control of, or otherwise affiliated with, the Reporting Person. As a result, those 1,029,511 shares are no longer beneficially owned by the Reporting Person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Woodland Hills Partner LLC, for which the Reporting Person serves as a managing member."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001962918-23-000036","document":"wk-form4_1696629327.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000196291823000036/wk-form4_1696629327.xml","form_type":"4"}},{"id":1801496,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-18T22:49:07.000Z","date":"2023-08-16","kind":"grant","planned":false,"acquired":true,"shares":842400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents Restricted Stock Units (RSUs). 1/4 of the RSUs will vest on May 15, 2024 and the remaining RSUs will vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":1612434,"source":{"system":"sec-edgar","filing":"0001962918-23-000021","document":"wk-form4_1692398937.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000196291823000021/wk-form4_1692398937.xml","form_type":"4"}},{"id":1883997,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-05-19T22:31:09.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20000,"derivative":{"exercise_price":0.56,"exercise_date":"2023-06-18","expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001593968-23-000844","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000159396823000844/primary_01.xml","form_type":"4"}},{"id":1896321,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":774788,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."}],"balance_after":774788,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Common Stock","underlying_shares":774788},"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896320,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":774788,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Class A Common Stock","underlying_shares":774788},"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896319,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"exercise","planned":false,"acquired":false,"shares":183433,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of\nthe Issuer's initial public offering of Common Stock (the \"IPO\"), all shares of preferred stock automatically converted into shares of Common\nStock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of\nthe Issuer's initial public offering of Common Stock (the \"IPO\"), all shares of preferred stock automatically converted into shares of Common\nStock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of\nthe Issuer's initial public offering of Common Stock (the \"IPO\"), all shares of preferred stock automatically converted into shares of Common\nStock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of\nthe Issuer's initial public offering of Common Stock (the \"IPO\"), all shares of preferred stock automatically converted into shares of Common\nStock."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Woodland Hills Partners LLC, for which the Reporting Person serves as a managing member."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":183433},"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896318,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"exercise","planned":false,"acquired":false,"shares":978314,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of\nthe Issuer's initial public offering of Common Stock (the \"IPO\"), all shares of preferred stock automatically converted into shares of Common\nStock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of\nthe Issuer's initial public offering of Common Stock (the \"IPO\"), all shares of preferred stock automatically converted into shares of Common\nStock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of\nthe Issuer's initial public offering of Common Stock (the \"IPO\"), all shares of preferred stock automatically converted into shares of Common\nStock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of\nthe Issuer's initial public offering of Common Stock (the \"IPO\"), all shares of preferred stock automatically converted into shares of Common\nStock."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Woodland Hills Partners LLC, for which the Reporting Person serves as a managing member."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":978314},"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896317,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":5070,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"Shares held directly by Susie Jun, Trustee of the Susie Jun Trust U/A/D September 23, 2005, for which the Reporting Person's spouse serves as trustee."}],"balance_after":5070,"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896316,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":5070,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"Shares held directly by Susie Jun, Trustee of the Susie Jun Trust U/A/D September 23, 2005, for which the Reporting Person's spouse serves as trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896315,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":349898,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Shares held directly by Susie Jun 2020 Gift Trust dtd 7/16/20, for which the Reporting Person serves as trustee."}],"balance_after":349898,"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896314,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":349898,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Shares held directly by Susie Jun 2020 Gift Trust dtd 7/16/20, for which the Reporting Person serves as trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896313,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":354969,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Shares held directly by Lin Family 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse shares voting and investment power."}],"balance_after":354969,"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896312,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":354969,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Shares held directly by Lin Family 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse shares voting and investment power."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896311,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":354969,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Shares held directly by Shao-Lee Lin 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse serves as trustee."}],"balance_after":354969,"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896310,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":354969,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Shares held directly by Shao-Lee Lin 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse serves as trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896309,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":677813,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held directly by Shao-Lee Lin, Trustee of the Shao-Lee Lin Trust u/a/d September 23, 2005, for which the Reporting Person serves as trustee."}],"balance_after":677813,"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896308,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":677813,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held directly by Shao-Lee Lin, Trustee of the Shao-Lee Lin Trust u/a/d September 23, 2005, for which the Reporting Person serves as trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896307,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":337179,"price":24.69,"value":8324949.51,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares that have been withheld by the Issuer to satisfy the income tax withholding obligations in connection with the net settlement of RSUs, and not a discretionary sale by the Reporting Person.  The Common Stock settled and RSUs held by the Reporting Person remain subject to the terms of a lock-up agreement by and between the Reporting Person and certain underwriters of the IPO."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Represents 303,237 shares of Common Stock and 466,797 RSUs after the net settlement of vested RSUs into shares of Common Stock upon the completion of the IPO.  The remaining RSUs will continue to settle into shares of Common Stock as they vest thereafter, subject to the Reporting Person's continued service."}],"balance_after":770034,"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896306,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":true,"shares":1107213,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":1107213,"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896305,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"other","planned":false,"acquired":false,"shares":1107213,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1896304,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-12T00:50:07.000Z","date":"2023-05-09","kind":"exercise","planned":false,"acquired":true,"shares":1161747,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of\nthe Issuer's initial public offering of Common Stock (the \"IPO\"), all shares of preferred stock automatically converted into shares of Common\nStock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of\nthe Issuer's initial public offering of Common Stock (the \"IPO\"), all shares of preferred stock automatically converted into shares of Common\nStock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Woodland Hills Partners LLC, for which the Reporting Person serves as a managing member."}],"balance_after":1161747,"source":{"system":"sec-edgar","filing":"0001209191-23-028862","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123028862/doc4.xml","form_type":"4"}},{"id":1903998,"issuer":{"id":79310,"kind":"organization","name":"ACELYRIN, Inc.","symbol":"SLRN"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-05-04T23:57:34.000Z","date":"2023-05-04","kind":"grant","planned":false,"acquired":true,"shares":774788,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock."}],"balance_after":774788,"derivative":{"exercise_price":18,"expiration_date":"2033-05-03","underlying":"Class A Common Stock","underlying_shares":774788},"source":{"system":"sec-edgar","filing":"0001209191-23-027509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000120919123027509/doc4.xml","form_type":"4"}},{"id":2131150,"issuer":{"id":76517,"kind":"organization","name":"Third Harmonic Bio, Inc.","symbol":"THRD"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-10-27T16:57:11.000Z","date":"2022-10-26","kind":"grant","acquired":true,"shares":13667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":13667,"derivative":{"exercise_price":17.83,"expiration_date":"2032-10-25","underlying":"Common Stock","underlying_shares":13667},"source":{"system":"sec-edgar","filing":"0001209191-22-054729","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1923840/000120919122054729/doc4.xml","form_type":"4"}},{"id":2237221,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-06-09T21:49:38.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest and become exercisable on the one-year anniversary of the grant date, subject to the reporting person's continuous service as a director."}],"balance_after":20000,"derivative":{"exercise_price":2.79,"exercise_date":"2023-06-07","expiration_date":"2032-06-07","underlying":"Surrozen, Inc. Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001593968-22-001109","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725092/000159396822001109/primary_01.xml","form_type":"4"}},{"id":3021548,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-09-28T17:25:45.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":10240,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":62.66,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":10240},"source":{"system":"sec-edgar","filing":"0001209191-20-052231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120052231/doc4.xml","form_type":"4"}},{"id":3021547,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-09-28T17:25:45.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":10240,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":31.77,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":10240},"source":{"system":"sec-edgar","filing":"0001209191-20-052231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120052231/doc4.xml","form_type":"4"}},{"id":3021546,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-09-28T17:25:45.000Z","date":"2020-09-28","kind":"disposition_to_issuer","acquired":false,"shares":20475,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the \"Issuer\"), Sanofi (\"Sanofi\") and Kortex Acquisition Corp. (\"Purchaser\") (the \"Merger Agreement\"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options."}],"balance_after":0,"derivative":{"exercise_price":27.81,"expiration_date":"2029-04-15","underlying":"Common Stock","underlying_shares":20475},"source":{"system":"sec-edgar","filing":"0001209191-20-052231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120052231/doc4.xml","form_type":"4"}},{"id":3118179,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-06-08T20:05:40.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":10240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":10240,"derivative":{"exercise_price":62.66,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":10240},"source":{"system":"sec-edgar","filing":"0001209191-20-035141","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919120035141/doc4.xml","form_type":"4"}},{"id":3304042,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Performance Restricted Stock Units (PSUs)","published_at":"2020-01-23T16:22:44.000Z","date":"2020-01-21","kind":"grant","acquired":true,"shares":12262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each PSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above.  The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above.  The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above.  The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022."}],"balance_after":12262,"derivative":{"underlying":"Ordinary Shares","underlying_shares":12262},"source":{"system":"sec-edgar","filing":"0001209191-20-004668","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120004668/doc4.xml","form_type":"4"}},{"id":3304041,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Ordinary Shares","published_at":"2020-01-23T16:22:44.000Z","date":"2020-01-21","kind":"tax_withholding","acquired":false,"shares":2716,"price":38.25,"value":103887.0,"ownership":{"direct":true},"balance_after":109668,"source":{"system":"sec-edgar","filing":"0001209191-20-004668","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120004668/doc4.xml","form_type":"4"}},{"id":3304040,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Ordinary Shares","published_at":"2020-01-23T16:22:44.000Z","date":"2020-01-21","kind":"grant","acquired":true,"shares":6129,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above.  The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022."}],"balance_after":112384,"source":{"system":"sec-edgar","filing":"0001209191-20-004668","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120004668/doc4.xml","form_type":"4"}},{"id":3316346,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Restricted Stock Units (RSU)","published_at":"2020-01-07T18:21:51.000Z","date":"2020-01-05","kind":"exercise","acquired":false,"shares":32362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2018."}],"balance_after":32363,"derivative":{"underlying":"Ordinary Shares","underlying_shares":32362},"source":{"system":"sec-edgar","filing":"0001209191-20-002344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120002344/doc4.xml","form_type":"4"}},{"id":3316345,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Restricted Stock Units (RSU)","published_at":"2020-01-07T18:21:51.000Z","date":"2020-01-05","kind":"exercise","acquired":false,"shares":17982,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2019."}],"balance_after":35966,"derivative":{"underlying":"Ordinary Shares","underlying_shares":17982},"source":{"system":"sec-edgar","filing":"0001209191-20-002344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120002344/doc4.xml","form_type":"4"}},{"id":3316344,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Restricted Stock Units (RSU)","published_at":"2020-01-07T18:21:51.000Z","date":"2020-01-04","kind":"exercise","acquired":false,"shares":17892,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSU's vest 1/4th annually on each anniversary of January 4, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSU's vest 1/4th annually on each anniversary of January 4, 2018."}],"balance_after":35784,"derivative":{"underlying":"Ordinary Shares","underlying_shares":17892},"source":{"system":"sec-edgar","filing":"0001209191-20-002344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120002344/doc4.xml","form_type":"4"}},{"id":3316343,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Restricted Stock Units (RSU)","published_at":"2020-01-07T18:21:51.000Z","date":"2020-01-03","kind":"grant","acquired":true,"shares":36284,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2020."}],"balance_after":36284,"derivative":{"underlying":"Ordinary Shares","underlying_shares":36284},"source":{"system":"sec-edgar","filing":"0001209191-20-002344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120002344/doc4.xml","form_type":"4"}},{"id":3316342,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Ordinary Shares","published_at":"2020-01-07T18:21:51.000Z","date":"2020-01-05","kind":"tax_withholding","acquired":false,"shares":38100,"price":36.1,"value":1375410.0,"ownership":{"direct":true},"balance_after":106255,"source":{"system":"sec-edgar","filing":"0001209191-20-002344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120002344/doc4.xml","form_type":"4"}},{"id":3316341,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Ordinary Shares","published_at":"2020-01-07T18:21:51.000Z","date":"2020-01-05","kind":"grant","acquired":true,"shares":35652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 5, 2020, the PSUs vested as to the number of shares reported above."}],"balance_after":144355,"source":{"system":"sec-edgar","filing":"0001209191-20-002344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120002344/doc4.xml","form_type":"4"}},{"id":3316340,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Ordinary Shares","published_at":"2020-01-07T18:21:51.000Z","date":"2020-01-05","kind":"exercise","acquired":true,"shares":50344,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":108703,"source":{"system":"sec-edgar","filing":"0001209191-20-002344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120002344/doc4.xml","form_type":"4"}},{"id":3316339,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Ordinary Shares","published_at":"2020-01-07T18:21:51.000Z","date":"2020-01-04","kind":"tax_withholding","acquired":false,"shares":8113,"price":36.1,"value":292879.3,"ownership":{"direct":true},"balance_after":58359,"source":{"system":"sec-edgar","filing":"0001209191-20-002344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120002344/doc4.xml","form_type":"4"}},{"id":3316338,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Ordinary Shares","published_at":"2020-01-07T18:21:51.000Z","date":"2020-01-04","kind":"exercise","acquired":true,"shares":17892,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,049 ordinary shares of the Issuer acquired by the reporting person on November 29, 2019 pursuant to an employee stock purchase program."}],"balance_after":66472,"source":{"system":"sec-edgar","filing":"0001209191-20-002344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120002344/doc4.xml","form_type":"4"}},{"id":3493801,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-06-11T18:57:57.000Z","date":"2019-06-11","kind":"grant","acquired":true,"shares":10240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":10240,"derivative":{"exercise_price":31.77,"expiration_date":"2029-06-10","underlying":"Common Stock","underlying_shares":10240},"source":{"system":"sec-edgar","filing":"0001209191-19-036237","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919119036237/doc4.xml","form_type":"4"}},{"id":3552565,"issuer":{"id":146423,"kind":"organization","name":"Principia Biopharma Inc.","symbol":"PRNB"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-04-18T16:23:35.000Z","date":"2019-04-16","kind":"grant","acquired":true,"shares":20475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":20475,"derivative":{"exercise_price":27.81,"expiration_date":"2029-04-15","underlying":"Common Stock","underlying_shares":20475},"source":{"system":"sec-edgar","filing":"0001209191-19-025238","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1510487/000120919119025238/doc4.xml","form_type":"4"}},{"id":3638737,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Ordinary Shares","published_at":"2019-02-22T17:23:02.000Z","date":"2019-02-20","kind":"tax_withholding","acquired":false,"shares":15795,"price":21.54,"value":340224.3,"ownership":{"direct":true},"balance_after":47531,"source":{"system":"sec-edgar","filing":"0001209191-19-012697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119012697/doc4.xml","form_type":"4"}},{"id":3638736,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Ordinary Shares","published_at":"2019-02-22T17:23:02.000Z","date":"2019-02-20","kind":"grant","acquired":true,"shares":35652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 20, 2019, the PSUs vested as to the number of shares reported above, upon the Issuer's determination that certain performance criteria had been met."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 20, 2019, the PSUs vested as to the number of shares reported above, upon the Issuer's determination that certain performance criteria had been met."}],"balance_after":63326,"source":{"system":"sec-edgar","filing":"0001209191-19-012697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119012697/doc4.xml","form_type":"4"}},{"id":3700287,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Restricted Stock Units (RSU)","published_at":"2019-01-08T20:40:03.000Z","date":"2019-01-05","kind":"exercise","acquired":false,"shares":32362,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2018."}],"balance_after":64725,"derivative":{"underlying":"Ordinary Shares","underlying_shares":32362},"source":{"system":"sec-edgar","filing":"0001209191-19-002935","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119002935/doc4.xml","form_type":"4"}},{"id":3700286,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Restricted Stock Units (RSU)","published_at":"2019-01-08T20:40:03.000Z","date":"2019-01-04","kind":"grant","acquired":true,"shares":53948,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2019."}],"balance_after":53948,"derivative":{"underlying":"Ordinary Shares","underlying_shares":53948},"source":{"system":"sec-edgar","filing":"0001209191-19-002935","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119002935/doc4.xml","form_type":"4"}},{"id":3700285,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Restricted Stock Units (RSU)","published_at":"2019-01-08T20:40:03.000Z","date":"2019-01-04","kind":"exercise","acquired":false,"shares":17891,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU's vest 1/4th annually on each anniversary of January 4, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSU's vest 1/4th annually on each anniversary of January 4, 2018."}],"balance_after":53676,"derivative":{"underlying":"Ordinary Shares","underlying_shares":17891},"source":{"system":"sec-edgar","filing":"0001209191-19-002935","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119002935/doc4.xml","form_type":"4"}},{"id":3700284,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Ordinary Shares","published_at":"2019-01-08T20:40:03.000Z","date":"2019-01-05","kind":"tax_withholding","acquired":false,"shares":14337,"price":20.39,"value":292331.43,"ownership":{"direct":true},"balance_after":27674,"source":{"system":"sec-edgar","filing":"0001209191-19-002935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119002935/doc4.xml","form_type":"4"}},{"id":3700283,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Ordinary Shares","published_at":"2019-01-08T20:40:03.000Z","date":"2019-01-05","kind":"exercise","acquired":true,"shares":32362,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":42011,"source":{"system":"sec-edgar","filing":"0001209191-19-002935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119002935/doc4.xml","form_type":"4"}},{"id":3700282,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Ordinary Shares","published_at":"2019-01-08T20:40:03.000Z","date":"2019-01-04","kind":"tax_withholding","acquired":false,"shares":8242,"price":20.39,"value":168054.38,"ownership":{"direct":true},"balance_after":9649,"source":{"system":"sec-edgar","filing":"0001209191-19-002935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119002935/doc4.xml","form_type":"4"}},{"id":3700281,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Ordinary Shares","published_at":"2019-01-08T20:40:03.000Z","date":"2019-01-04","kind":"exercise","acquired":true,"shares":17891,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":17891,"source":{"system":"sec-edgar","filing":"0001209191-19-002935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119002935/doc4.xml","form_type":"4"}},{"id":3944329,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Restricted Stock Units (RSU)","published_at":"2018-05-07T20:48:44.000Z","date":"2018-05-03","kind":"grant","acquired":true,"shares":97087,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."},{"field":"date","element":"transactionDate","label":"F2","text":"The RSU's were approved by the Issuer's Compensation Committee on January 5, 2018, subject to shareholder approval of certain amendments to the Issuer's 2014 Equity Incentive Plan (the \"Plan\") under which the RSU's were granted. The Issuer's shareholders approved the amendments to the Plan on May 3, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU's vest 1/3rd annually on each anniversary of January 5, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each RSU represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":97087,"derivative":{"underlying":"Ordinary Shares","underlying_shares":97087},"source":{"system":"sec-edgar","filing":"0001209191-18-028490","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919118028490/doc4.xml","form_type":"4"}},{"id":4105504,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Restricted Stock Units","published_at":"2018-01-05T17:04:03.000Z","date":"2018-01-04","kind":"grant","acquired":true,"shares":71567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the restricted stock units shall vest in four equal annual installments, beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":71567,"derivative":{"underlying":"Ordinary shares","underlying_shares":71567},"source":{"system":"sec-edgar","filing":"0001209191-18-002497","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919118002497/doc4.xml","form_type":"4"}},{"id":4105503,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":23228,"kind":"person","name":"Lin Shao-Lee","position":1,"cik":"0001725092","reported_name":"Lin Shao-Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of R&D and CSO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-05T17:04:03.000Z","date":"2018-01-04","kind":"grant","acquired":true,"shares":146685,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":146685,"derivative":{"exercise_price":15.37,"expiration_date":"2028-01-03","underlying":"Ordinary shares","underlying_shares":146685},"source":{"system":"sec-edgar","filing":"0001209191-18-002497","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919118002497/doc4.xml","form_type":"4"}}]}